Cargando…
Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenog...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/ https://www.ncbi.nlm.nih.gov/pubmed/30845999 http://dx.doi.org/10.1186/s12885-019-5401-2 |
_version_ | 1783401519957147648 |
---|---|
author | Matossian, Margarite D. Burks, Hope E. Elliott, Steven Hoang, Van T. Bowles, Annie C. Sabol, Rachel A. Wahba, Bahia Anbalagan, Muralidharan Rowan, Brian Abazeed, Mohamed E. Bunnell, Bruce A. Moroz, Krzysztof Miele, Lucio Rhodes, Lyndsay V. Jones, Steven D. Martin, Elizabeth C. Collins-Burow, Bridgette M. Burow, Matthew E. |
author_facet | Matossian, Margarite D. Burks, Hope E. Elliott, Steven Hoang, Van T. Bowles, Annie C. Sabol, Rachel A. Wahba, Bahia Anbalagan, Muralidharan Rowan, Brian Abazeed, Mohamed E. Bunnell, Bruce A. Moroz, Krzysztof Miele, Lucio Rhodes, Lyndsay V. Jones, Steven D. Martin, Elizabeth C. Collins-Burow, Bridgette M. Burow, Matthew E. |
author_sort | Matossian, Margarite D. |
collection | PubMed |
description | BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenografts (PDXs), due to their genomic and transcriptomic fidelity to the tumors from which they are derived, are poised to improve the preclinical testing of drug-target combinations in translational models. Despite the previous development of breast and TNBC PDX models, those derived from patients with demonstrated health-disparities are lacking. METHODS: We use an aggressive TNBC PDX model propagated in SCID/Beige mice that was established from an African-American woman, TU-BcX-2 K1, and assess its metastatic potential and drug sensitivities under distinct in vitro conditions. Cellular derivatives of the primary tumor or the PDX were grown in 2D culture conditions or grown in mammospheres 3D culture. Flow cytometry and fluorescence staining was used to quantify cancer stem cell-like populations. qRT-PCR was used to describe the mesenchymal gene signature of the tumor. The sensitivity of TU-BcX-2 K1-derived cells to anti-neoplastic oncology drugs was compared in adherent cells and mammospheres. Drug response was evaluated using a live/dead staining kit and crystal violet staining. RESULTS: TU-BcX-2 K1 has a low propensity for metastasis, reflects a mesenchymal state, and contains a large burden of cancer stem cells. We show that TU-BcX-2 K1 cells have differential responses to cytotoxic and targeted therapies in 2D compared to 3D culture conditions insofar as several drug classes conferred sensitivity in 2D but not in 3D culture, or cells grown as mammospheres. CONCLUSIONS: Here we introduce a new TNBC PDX model and demonstrate the differences in evaluating drug sensitivity in adherent cells compared to mammosphere, or suspension, culture. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5401-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6407287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64072872019-03-21 Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model Matossian, Margarite D. Burks, Hope E. Elliott, Steven Hoang, Van T. Bowles, Annie C. Sabol, Rachel A. Wahba, Bahia Anbalagan, Muralidharan Rowan, Brian Abazeed, Mohamed E. Bunnell, Bruce A. Moroz, Krzysztof Miele, Lucio Rhodes, Lyndsay V. Jones, Steven D. Martin, Elizabeth C. Collins-Burow, Bridgette M. Burow, Matthew E. BMC Cancer Research Article BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive subtype with limited therapeutic options. Experimental preclinical models that recapitulate their tumors of origin can accelerate target identification, thereby potentially improving therapeutic efficacy. Patient-derived xenografts (PDXs), due to their genomic and transcriptomic fidelity to the tumors from which they are derived, are poised to improve the preclinical testing of drug-target combinations in translational models. Despite the previous development of breast and TNBC PDX models, those derived from patients with demonstrated health-disparities are lacking. METHODS: We use an aggressive TNBC PDX model propagated in SCID/Beige mice that was established from an African-American woman, TU-BcX-2 K1, and assess its metastatic potential and drug sensitivities under distinct in vitro conditions. Cellular derivatives of the primary tumor or the PDX were grown in 2D culture conditions or grown in mammospheres 3D culture. Flow cytometry and fluorescence staining was used to quantify cancer stem cell-like populations. qRT-PCR was used to describe the mesenchymal gene signature of the tumor. The sensitivity of TU-BcX-2 K1-derived cells to anti-neoplastic oncology drugs was compared in adherent cells and mammospheres. Drug response was evaluated using a live/dead staining kit and crystal violet staining. RESULTS: TU-BcX-2 K1 has a low propensity for metastasis, reflects a mesenchymal state, and contains a large burden of cancer stem cells. We show that TU-BcX-2 K1 cells have differential responses to cytotoxic and targeted therapies in 2D compared to 3D culture conditions insofar as several drug classes conferred sensitivity in 2D but not in 3D culture, or cells grown as mammospheres. CONCLUSIONS: Here we introduce a new TNBC PDX model and demonstrate the differences in evaluating drug sensitivity in adherent cells compared to mammosphere, or suspension, culture. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5401-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-07 /pmc/articles/PMC6407287/ /pubmed/30845999 http://dx.doi.org/10.1186/s12885-019-5401-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Matossian, Margarite D. Burks, Hope E. Elliott, Steven Hoang, Van T. Bowles, Annie C. Sabol, Rachel A. Wahba, Bahia Anbalagan, Muralidharan Rowan, Brian Abazeed, Mohamed E. Bunnell, Bruce A. Moroz, Krzysztof Miele, Lucio Rhodes, Lyndsay V. Jones, Steven D. Martin, Elizabeth C. Collins-Burow, Bridgette M. Burow, Matthew E. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title | Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title_full | Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title_fullStr | Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title_full_unstemmed | Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title_short | Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
title_sort | drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407287/ https://www.ncbi.nlm.nih.gov/pubmed/30845999 http://dx.doi.org/10.1186/s12885-019-5401-2 |
work_keys_str_mv | AT matossianmargarited drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT burkshopee drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT elliottsteven drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT hoangvant drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT bowlesanniec drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT sabolrachela drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT wahbabahia drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT anbalaganmuralidharan drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT rowanbrian drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT abazeedmohamede drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT bunnellbrucea drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT morozkrzysztof drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT mielelucio drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT rhodeslyndsayv drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT jonesstevend drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT martinelizabethc drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT collinsburowbridgettem drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel AT burowmatthewe drugresistanceprofilingofanewtriplenegativebreastcancerpatientderivedxenograftmodel |